EMA Panel Backs Fostamatinib (Tavalisse) for Chronic ITP

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of fostamatinib disodium hexahydrate (Tavalisse, Rigel Pharmaceuticals, Inc) to treat adults with chronic immune thrombocytopenia (ITP) who fail other treatments.

- By Megan Brooks for Medscape.com

Read More